What changed in ICH E6(R3)?

ICH E6(R3) keeps the core duties of good clinical practice but builds quality into trial design and scales oversight to each trial's risks (ICH E6(R3) Principle 6; ICH E6(R3) Principle 7).

It also gives data governance its own section, speaks of essential records, and allows varied consent formats (ICH E6(R3) 4.3; ICH E6(R3) C.2.5; ICH E6(R3) 2.8.1(c)).

The main changes, one by one

  • Structure: E6(R3) is a set of principles with Annex 1 for interventional trials, and Annex 2 adds considerations for decentralized elements, pragmatic elements and real world data (EMA, ICH E6 scientific guideline page).
  • Quality by design: quality is built into the scientific and operational design of a trial from the start, around the factors critical to quality (ICH E6(R3) Principle 6).
  • Risk proportionality: processes, oversight and documentation are proportionate to the risks to participants and to the reliability of results (ICH E6(R3) Principle 7).
  • Data governance: responsibilities for computerised systems are clear and documented (ICH E6(R3) 4.3), users are trained (ICH E6(R3) 4.3.2), and validation is based on intended use and risk (ICH E6(R3) 4.3.4).
  • Essential records: the record set is scaled to the trial's design and risk (ICH E6(R3) C.1.1), with some records in place before the trial starts (ICH E6(R3) C.2.5).
  • Consent: text, images, video and interactive formats may be used (ICH E6(R3) 2.8.1(c)), and the investigator assures the participant's identity in person or remotely (ICH E6(R3) 2.8.1(e)).
  • Investigator oversight: the investigator oversees delegated people and parties in proportion to the importance and risk of their tasks (ICH E6(R3) 2.3.1), documents delegation in proportion too (ICH E6(R3) 2.3.3), and defines what counts as source records before the trial (ICH E6(R3) 2.12.2).
  • Service providers: sponsors document agreements with service providers before the work starts (ICH E6(R3) 3.6.1).

What stayed the same

The core protections did not change. A trial still needs dated ethics committee approval before it starts (ICH E6(R3) 2.4.2), consent is still documented before participation (ICH E6(R3) 2.8.7), the investigator still keeps responsibility for delegated work (ICH E6(R3) 2.3.1), and serious adverse events are still reported to the sponsor (ICH E6(R3) 2.7.2(b)).

The guideline also speaks of trial participants rather than subjects, which puts the people taking part at the center of the text.

When it applies

ICH adopted the principles and Annex 1 in January 2025 (ICH E6(R3), document history). The EU applied them from 23 July 2025, and FDA published E6(R3) as final guidance in September 2025 (EMA, ICH E6 scientific guideline page; FDA, E6(R3) guidance page). Other regulators set their own dates, so check yours.

What a site can do now

  • Update GCP training for everyone on a delegation log to E6(R3), and keep the record with its date.
  • Agree with each sponsor what your source records are before the study starts.
  • Review how your site keeps and controls its computerised systems and who can access them.
  • Practice the judgment calls E6(R3) now leaves to people, such as choosing a proportionate response to a deviation.

Questions people also ask

Is ICH E6(R3) a big change for site staff?

The duties are familiar, but more of them now call for judgment about risk. Staff who know the rules still need practice choosing the proportionate response (ICH E6(R3) Principle 7).

What does quality by design mean in E6(R3)?

Building quality into how a trial is designed and run from the start, focused on the factors that matter most for participant protection and reliable results, rather than checking for problems afterwards (ICH E6(R3) Principle 6).

Does E6(R3) require electronic consent?

No. It allows varied approaches, including text, images, video and interactive formats, and computerised consent can be offered with a paper alternative (ICH E6(R3) 2.8.1(c)).

Where is the full text?

The final guideline is published by ICH, and the EMA and FDA pages list it for their regions. All three are linked under Primary sources below.

Primary sources

  • ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
  • ICH E6 Good clinical practice: scientific guideline (European Medicines Agency): https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline
  • E6(R3) Good Clinical Practice, final guidance (U.S. Food and Drug Administration): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp

Last reviewed

2026-11-14